

Moritz Binder

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1923676/moritz-binder-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

891
citations

17
h-index

27
g-index

106
ext. papers

1,237
ext. citations

4.9
avg, IF

3.79
L-index

#	Paper	IF	Citations
94	A Population-Based Study of Acute Panmyelosis with Myelofibrosis in the United States: 2004-2015.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
93	A simple additive staging system for newly diagnosed multiple myeloma.. <i>Blood Cancer Journal</i> , 2022 , 12, 21	7	4
92	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , 2022 ,	10.7	2
91	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. <i>Leukemia Research</i> , 2022 , 106818	2.7	0
90	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.. <i>Nature Communications</i> , 2022 , 13, 1434	17.4	0
89	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021 , 138, 2707-2707	2.2	
88	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021 , 138, 3805-3805	2.2	
87	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3771-3771	2.2	0
86	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021 , 138, 3773-3773	2.2	
85	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2021 , 138, 1470-1470	2.2	
84	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1619-1619	2.2	
83	Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project. <i>Blood</i> , 2021 , 138, 2164-2164	2.2	
82	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021 , 138, 119-119	2.2	
81	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , 2021 , 138, 3838-3838	2.2	1
80	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2021 ,	10.7	5
79	Asxl1 loss cooperates with oncogenic Nras in mice to reprogram immune microenvironment and drive leukemic transformation. <i>Blood</i> , 2021 ,	2.2	1
78	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. <i>Blood Advances</i> , 2021 , 5, 2272-2278	7.8	3

77	A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004 to 2015.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19003-e19003	2.2	
76	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021 , 12, 2901	17.4	12
75	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. <i>Leukemia</i> , 2021 , 35, 644-649	10.7	6
74	The Prognostic Role of Structural Variants Identified by NGS and FISH in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
73	Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms. <i>American Journal of Hematology</i> , 2021 , 96, E392-E396	7.1	2
72	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 5425-5430	7.8	10
71	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>British Journal of Haematology</i> , 2020 , 189, e104-e108	4.5	4
70	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. <i>Blood</i> , 2020 , 136, 1477-1486	2.2	21
69	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. <i>Leukemia</i> , 2020 , 34, 2519-2524	10.7	10
68	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. <i>American Journal of Hematology</i> , 2020 , 95, E86-E89	7.1	2
67	Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2020 , 136, 31-32	2.2	
66	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020 , 136, 35-36	2.2	
65	ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility. <i>Blood</i> , 2020 , 136, 27-28	2.2	1
64	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 30-31	2.2	2
63	Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. <i>Blood</i> , 2020 , 136, 909-913	2.2	28
62	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 2236-2244	7.8	7
61	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. <i>Blood Advances</i> , 2020 , 4, 5716-5721	7.8	5
60	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. <i>American Journal of Hematology</i> , 2020 , 95, E31-E34	7.1	1

59	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. <i>Leukemia</i> , 2020 , 34, 1407-1421	10.7	40
58	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020 , 10, 121	7	7
57	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. <i>Leukemia</i> , 2020 , 34, 656-661	10.7	17
56	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 41	7	16
55	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2960-2967	1.9	2
54	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. <i>American Journal of Hematology</i> , 2019 , 94, 767-779	7.1	27
53	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019 , 185, 254-260	4.5	8
52	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 3003-3003	2.2	1
51	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019 , 134, 72-72	2.2	1
50	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019 , 134, 4182-4182	2.2	1
49	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4396-4396	2.2	
48	Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019 , 134, 4232-4232	2.2	
47	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019 , 134, 3005-3005	2.2	
46	Epigenomic Determinants of Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019 , 134, 2987-2987	2.2	
45	Germline Variation Predicts Treatment Response in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4397-4397	2.2	
44	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019 , 134, 2981-2981		
43	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019 , 134, 1710-1710	2.2	
42	The Transcriptome of Immunomodulator-Resistant Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1772-1772	2.2	

41	Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3061-3061	2.2	
40	Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide. <i>Arthritis Research and Therapy</i> , 2019 , 21, 262	5.7	4
39	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 306-311	7.1	9
38	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 889-894	7.1	8
37	Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. <i>Gastrointestinal Endoscopy</i> , 2018 , 88, 55-61	5.2	8
36	Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. <i>Gut</i> , 2018 , 67, 441-446	19.2	23
35	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 59	7	115
34	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3159-3159		
33	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3158-3158	2.2	
32	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4497-4497	2.2	
31	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1902-1902	2.2	
30	Relative Morphokinetics Assessed by Time-Lapse Imaging Are Altered in Embryos From Patients With Endometriosis. <i>Reproductive Sciences</i> , 2018 , 25, 1279-1285	3	16
29	Mutational landscape reflects the biological continuum of plasma cell dyscrasias. <i>Blood Cancer Journal</i> , 2017 , 7, e537	7	16
28	Optimization of design and production strategies for novel adeno-associated viral display peptide libraries. <i>Gene Therapy</i> , 2017 , 24, 470-481	4	12
27	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017 , 92, 752-758	7.1	11
26	Oesophageal lichen planus: the efficacy of topical steroid-based therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 310-318	6.1	6
25	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017 , 7, e600	7	43
24	Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 228-234	3	20

23	High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). <i>Leukemia</i> , 2017 , 31, 846-852	10.7	88
22	Validation of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 777-8	6.9	6
21	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2016 , 6, e401	7	21
20	Association of CYP17A1 single nucleotide polymorphism (SNP) with response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16603-e16603	2.2	1
19	Prognostic impact of genetic variation in steroidogenic enzymes in advanced stage prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16605-e16605	2.2	
18	Genetic variation in sex hormone receptor genes and association with enzalutamide response in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16606-e16606	2.2	
17	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016 , 128, 5615-5615	2.2	
16	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016 , 128, 3255-3255	2.2	
15	Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	20
14	Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. <i>American Journal of Hematology</i> , 2016 , 91, 551-5	7.1	20
13	Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. <i>Leukemia</i> , 2016 , 30, 2232-2234	10.7	18
12	61-Year-Old Man With Right Knee Pain and Chronic Anemia. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1640-1644	4.4	
11	Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. <i>Blood Cancer Journal</i> , 2015 , 5, e285	7	68
10	Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. <i>Cancer Causes and Control</i> , 2015 , 26, 1751-9	2.8	5
9	Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. <i>Leukemia</i> , 2015 , 29, 696-704	10.7	26
8	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015 , 90, 888-91	7.1	14
7	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4176-4176	2.2	
6	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 5254-5254	2.2	

5	Meta-Analysis of HLA-Mismatched Compared to HLA-Matched Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 1248-1248	2.2	
4	Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. <i>Arthritis Care and Research</i> , 2013 , 65, 281-7	4.7	12
3	CCL18 -- potential biomarker of fibroinflammatory activity in chronic periaortitis. <i>Journal of Rheumatology</i> , 2012 , 39, 1407-12	4.1	13
2	Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 311-2	2.4	27
1	RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis		2